The
catalytic enantioselective synthesis of 3-aryl-substituted
pyrrolopyrimidines (PPYs), a common motif in drug discovery, is achieved
through a kinetic resolution via quaternary ammonium salt-catalyzed
nucleophilic aromatic substitution (S<sub>N</sub>Ar). Both enantioenriched
products and starting materials can be functionalized with no observed
racemization to give enantiodivergent access to diverse chiral analogues
of an important class of kinase inhibitor. One of the compounds was
found to be a potent and selective inhibitor of breast tumor kinase
